Union of forces
Vascular anomalies or birthmarks have been recognized by mankind for centuries. A major progress in our understanding of such anomalies occurred in 1982, when Mulliken and Glowacki 1 distinguished between two main types: tumours and malformations. Venous malformations (VMs) are the most frequent vascular anomalies seen in physicians' offices. They can be small and asymptomatic or large and can present as a disturbing cosmetic problem. However, they can also cause pain, bleeding, functional impairment, severe disfiguration, diffuse intravascular coagulation, deep vein thrombosis or pulmonary embolism, affecting the quality of life of the patients and leading to severe discomfort, loss of working days, disability or even death.
The excellent article on VMs, published in this issue of Phlebology by Dompmartin, Vikkula and Boon, a dermatologist, a genetic researcher and a plastic surgeon, is a summary of the important work these authors have conducted for years on VMs. 2 This article as well as other recent reviews on the topic 3 -6 illustrate both the increasing interest and the rapidly accumulating new information on this fascinating and challenging clinical problem. Not long ago Phlebology devoted a special issue to VMs, guest edited by B B Lee, 7 while a recent consensus guideline of the International Union of Phlebology 8 (IUP) helped to clarify some of the controversies that exist on classification, diagnostic tests, imaging studies and on the role of different interventions used for the treatment of VMs.
The classification of VMs remains a confusing issue because of the wide spectrum of anomalies: no two malformations are identical. There is agreement that these are low-flow malformations and that they can be sporadic or familial. They can be unifocal or multifocal and some present with combined anomalies involving veins, lymphatics, capillaries, arteriovenous shunts or the arteries. Some are part of a clinical syndrome with associated non-vascular malformations, such as Klippel-Trenaunay syndrome (limb hypertrophy with capillaro-venous-lymphatic malformations) 5 or Mafucci syndrome (multiple enchondromas with haemangioendotheliomas and a high propensity for malignancy). 2, 9 Some confusion exists on why some mixed vascular anomalies may behave differently in the context of a syndrome than when they just stand alone.
There is disagreement on the importance of the anatomy of these lesions and if VMs should include anomalies of larger venous trunks as proposed in the revised Hamburg classification, endorsed by the IUP Consensus Group on VMs. 8 Hard to understand why truncular venous anomalies would not be considered important VMs. Dompmartin et al. 2 believe that clinical presentation, genetics, aetiopathogenesis and rheology are more important for classification than a hypothesis about the time of arrest in development of the venous system or adopting a distinction between truncular and extratruncular lesions. None of the proposed classification schemes are perfect nor are they all inclusive; progress in genetics and imaging studies and more information on normal and abnormal development will force us to continuously re-evaluate our knowledge in this field and change our classification to the most practical one that helps with management.
Techniques of vascular imaging have been perfected in recent years; duplex scanning has become the initial test not only to confirm the presence of low flow and the absence of arteriovenous shunting, but also to search for any truncular venous anomalies that may influence treatment strategy. Magnetic resonance imaging (MRI) with spin-echo T1-and T2-weighted sequences remains the most important imaging test for VMs that can be complemented with MR venography that may give useful information on venous drainage of the lesions and on truncular venous channel anomalies especially in those patients who have VMs affecting the pelvis and the limbs. Contrast venography for diagnostic purposes is used selectively. MR lymphangiography has been emerging as a useful test to image the lymphatic system, in addition to isotope lymphangiography, another semi-quantitative and minimally invasive test that provides useful information of lymphatic transport. Contrast studies to image the lymphatic system should be used rarely and only in patients in whom they directly influences management.
Observing elevated levels of D-dimer in such a high number of patients with VMs is new and exciting. 2 Is this indeed a new diagnostic biomarker of VMs or is it just a marker of thrombus formed in patients with extensive VMs and associated thrombotic complications? Further studies by independent groups will provide the final answer to this important question.
Sclerotherapy of VMs has rapidly progressed and the efficiency of absolute alcohol has been Phlebology 2010;25:217-218 confirmed by several authors. 10 -12 Side-effects, however, have been significant, especially when alcohol was injected close to the skin or next to major nerves. 12 Foam sclerotherapy has revolutionized vein treatment in phlebology and its successful use for VMs and persistent embryonic veins has been also reported. 13 -15 Whether the better treatment will be injection of polidocanol or sotradecol, mixed with air or carbon dioxide, in the form of a regular foam or as a microfoam, remains to be demonstrated. Side-effects of foam, visual, cerebral or pulmonary, also have to be sorted out. However, it is obvious that the use of alcohol, a potentially dangerous solution in inexperienced hands, will diminish or it will be used with the technique of Dompmartin et al., 2 as presented here, to decrease the amount of alcohol injected and improve efficacy and safety in the form of ethylcellulose-ethanol.
Like in patients with chronic venous disease, the role of open venous surgery in the treatment of VMs will further diminish. 16 Some patients, who are not treated with sclerotherapy, but need intervention because of symptoms or severe cosmetic deformity, may benefit from laser or radiofrequency ablation while some of those who have localized disease may still best be treated with open surgery.
During the past decade progress in prediction, diagnosis and treatment of VMs as well as in prevention of its complications has been spectacular due to advances in genetics, improved knowledge of the aetiopathogenesis of both the inherited and sporadic vascular malformations, better diagnostic techniques, identification of biomarkers, and the introduction of less invasive and more effective therapies. Advancement in this field can also be attributed to the increasingly close collaboration between clinicians and laboratory researchers, interested in vascular malformations, an example so beautifully demonstrated by the different affiliation of the authors who contributed to the article printed in this issue on VMs. 2 Perhaps more than in any other field, patients with vascular malformations greatly benefit from multidisciplinary collaboration and management, a concept that has been emphasized by others as well. 8 Team approach in medicine is not new. Doctor William Mayo talked about it 100 years ago: '. . . in order that the sick may have the benefit of advancing knowledge, union of forces is necessary' (William J Mayo MD, 1910 ). 17 
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